Sign in

ZYNE on NASDAQ

Zynerba Pharmaceuticals

American pharmaceutical preparations company based in Radnor, founded in 20141

In its 2023 annual report the company says: “We are the leader in pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, or FXS, and chromosome 22q11.2 deletion syndrome, or 22q.”48 Its shares trade on NASDAQ under the symbol ZYNE.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Jan 1, 2014Founded1

Compare with Incannex Healthcare Inc., Actinium Pharmaceuticals, Inc. or Citius Pharmaceuticals, Inc., or pick any stock.

  • TickerZYNE on NASDAQ1
  • IndustryPharmaceutical Preparations1
  • HeadquartersRadnor1
  • Websitezynerba.com
  • Legal formDelaware corporation1
  • Incorporated inDE4
  • Business address80 W. Lancaster Avenue, Suite 300, Devon, Pa 193334
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • LEI549300JLJ5VQU2CN60163
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States3
  • Registered withDivision of Corporations, Department of State, 42942303

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2018

-46974.2%Operating margin5
-46408.3%Net margin5
-69.3%Return on equity6
-$32.7MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2018

  • Research and development100¢$27.2M

Out of $86.0K in revenue.57 The company lost money this year.

Financial statements

Revenue75$86.0K in 2018+1086% since 2016
0$25.0K$50.0K$75.0K$100.0K2016: $7.2K$7.2K20162017: $0$020172018: $86.0K$86.0K2018
Operating income785-$40.4M in 2018+74% since 2016
-$60.0M-$40.0M-$20.0M02016: -$23.2M-$23.2M20162017: -$32.8M-$32.8M2017+41%2018: -$40.4M-$40.4M2018+23%
Net income785-$39.9M in 2018+71% since 2016
-$40.0M-$30.0M-$20.0M-$10.0M02016: -$23.4M-$23.4M20162017: -$32.0M-$32.0M2017+37%2018: -$39.9M-$39.9M2018+25%
Fiscal year201620172018
Revenue$7.2K7$07$86.0K5
Research and development$16.8M7$22.8M8$27.2M5
Operating expenses
Operating income-$23.2M7-$32.8M8-$40.4M5
Income before tax
Income tax-$27.5K7$07$07
Net income-$23.4M7-$32.0M8-$39.9M5
Earnings per share
Earnings per share (diluted)
Shares (weighted, basic)
Shares (weighted, diluted)

Compare Zynerba Pharmaceuticals with another company

Corporate structure

Zynerba Pharmaceuticals is part of a group headed by Harmony Biosciences Holdings, Inc.. 5 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Zynerba Pharmaceuticals

  • Harmony Biosciences Holdings, Inc. Plymouth Meeting, Pennsylvania
    • Zynerba Pharmaceuticals Easttown Township, Pennsylvania, United States
    • Epygenix Therapeutics, Inc. Subsidiary · Wyoming, United States
    • Harmony Biosciences Management, Inc. Subsidiary · Delaware, United States
    • Harmony Biosciences, LLC Subsidiary · Delaware, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Zynerba Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.5M12 Dec 31, 2022$1.2M12 Dec 31, 2021+19.8%
Accumulated depreciation$1.1M12 Dec 31, 2022$844.6K12 Dec 31, 2021+26.0%
Property and equipment, net$409.6K12 Dec 31, 2022$385.8K12 Dec 31, 2021+6.2%
Operating-lease assets (leased space)$336.2K12 Dec 31, 2022$565.8K12 Dec 31, 2021−40.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$50.6M12 Dec 31, 2022$67.8M12 Dec 31, 2021−25.3%

Leadership

Who has led Zynerba Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Armando Anido2022

Chair

  1. Armando Anido2015–2023

President

  1. Terri B. Sebree2015–2023

Chief financial officer

  1. Richard A. Baron2015
  2. James E. Fickenscher2016–2023
201520202025
Board members and other officers (9)

Former names

  • Zynerba Pharmeceuticals, Inc.Oct 9, 2014 to Jun 30, 20154

Timeline

  1. Oct 11, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights27
  2. Aug 29, 20238-K Shareholder vote28
  3. Aug 14, 20238-K Entered a material agreement; Executive or director change; Regulation FD disclosure29
  4. Jun 14, 20238-K Shareholder vote30
  5. May 15, 20238-K Results of operations; Other events31
  6. May 4, 20238-K Listing notice or transfer32
  7. Mar 28, 20238-K Results of operations; Other events33
  8. Mar 13, 20238-K Regulation FD disclosure34
  9. Jan 9, 20238-K Other events35
  10. Dec 21, 20228-K Other events36
  11. Dec 5, 20228-K Other events37
  12. Nov 15, 20228-K Other events38
  13. Jul 20, 2022New chief executive Armando Anido becomes CEO13
  14. Jan 1, 2014Founded Founded1

Calendar

When it reported results

  1. May 15, 2023Reported quarterly or annual results31
  2. Mar 28, 2023Reported quarterly or annual results33
  3. Nov 14, 2022Reported quarterly or annual results39
  4. Aug 10, 2022Reported quarterly or annual results40
  5. May 16, 2022Reported quarterly or annual results41
  6. Mar 1, 2022Reported quarterly or annual results42
  7. Nov 15, 2021Reported quarterly or annual results43

Drug trials and FDA: recently

  1. Nov 9, 2022Phase 2 trial completed Phase 2 trial of ZYN002 in 22Q11.2 Deletion Syndrome, run by Harmony Biosciences Management, Inc.: primary completion Nov 9, 2022, results posted Mar 9, 2026 (ClinicalTrials.gov NCT05149898).44

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

140 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 26 major events, 56 insider forms, 4 large holders, 46 other. The latest 20:

  1. Feb 8, 2024SC 13G/A EDGAR
  2. Oct 19, 202315-12G EDGAR
  3. Oct 11, 2023EFFECT EDGAR
  4. Oct 11, 20234 EDGAR
  5. Oct 11, 20234 EDGAR
  6. Oct 11, 20234 EDGAR
  7. Oct 11, 20234 EDGAR
  8. Oct 11, 20234 EDGAR
  9. Oct 11, 20234 EDGAR
  10. Oct 11, 20234 EDGAR
  11. Oct 11, 20234 EDGAR
  12. Oct 11, 20234 EDGAR
  13. Oct 11, 20234 EDGAR
  14. Oct 11, 20234 EDGAR
  15. Oct 11, 20234 EDGAR
  16. Oct 11, 2023POS AM EDGAR
  17. Oct 11, 2023S-8 POS EDGAR
  18. Oct 11, 2023S-8 POS EDGAR
  19. Oct 11, 2023S-8 POS EDGAR
  20. Oct 11, 2023S-8 POS EDGAR

The 140 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

26 open-market trades by officers, directors and large owners since October 2021: 0 buys and 26 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 13, 2023Sebree Terri BPresidentSale12,401$1.33$16.5KForm 4
Sep 13, 2023Rosenberger BrianVP, Commercial & Business Dev.Sale6,411$1.33$8.5KForm 4
Sep 13, 2023Fickenscher James EChief Financial OfficerSale8,998$1.33$12.0KForm 4
Sep 13, 2023Jones Kenneth TSee RemarksSale2,505$1.33$3.3KForm 4
Sep 13, 2023ANIDO ARMANDOChairman & Chief Exec. OfficerSale17,830$1.33$23.7KForm 4
Jun 14, 2023Stephenson PamelaDirectorSale115$0.35$40Form 4
Jun 14, 2023MOCH KENNETH IDirectorSale115$0.35$40Form 4
Jun 14, 2023KISNER DANIEL LDirectorSale115$0.35$40Form 4
Jun 14, 2023FEDERICI WILLIAM JDirectorSale115$0.35$40Form 4
Jun 14, 2023Butler John P.DirectorSale115$0.35$40Form 4
Jun 14, 2023COOPER WARREN DDirectorSale115$0.35$40Form 4
Feb 15, 2023Parker Albert PChief Legal OfficerSale3,173$0.54$1.7KForm 4
Jan 23, 2023Sebree Terri BPresidentSale24,661$0.60$14.8KForm 4
Jan 23, 2023Fickenscher James EChief Financial OfficerSale17,769$0.60$10.7KForm 4
Jan 23, 2023Rosenberger BrianVP, Commercial & Business Dev.Sale12,663$0.60$7.6KForm 4
Jan 23, 2023ANIDO ARMANDOChairman & Chief Exec. OfficerSale35,453$0.60$21.3KForm 4
Jul 19, 2022Sebree Terri BPresidentSale8,281$1.10$9.1KForm 4
Jul 19, 2022Rosenberger BrianVP, Commercial & Business Dev.Sale4,289$1.10$4.7KForm 4
Jul 19, 2022Fickenscher James EChief Financial OfficerSale6,013$1.10$6.6KForm 4
Jul 19, 2022ANIDO ARMANDOChairman & Chief Exec. OfficerSale11,899$1.10$13.1KForm 4

All 26 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Zynerba Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARZynerba Pharmaceuticals, Inc.2
  • CIK0001621443
  • Employer ID (EIN)26-03894332
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address80 W. Lancaster Avenue, Suite 300, Devon, PA 193332
  • Phone484-581-75052
  • Shares outstanding53,939,431 as of Aug 9, 202310
  • Public float$47.7M as of Jun 30, 202212
  • On EDGAR sinceOct 9, 20142
  • Filings526 in all: 4 (171), 8-K (144), 10-Q (25), SC 13G/A (25), DEFA14A (21), 3 (17), SC 13G (11), CORRESP (10)2
    All 39 form types

    S-8 (10), S-8 POS (10), UPLOAD (9), 10-K (8), 424B5 (8), DEF 14A (8), EFFECT (7), SC 14D9/A (6), S-3 (4), SC TO-T/A (4), PRE 14A (3), DRSLTR (2), POS AM (2), S-1/A (2), SC TO-C (2), SC14D9C (2), 15-12G (1), 25-NSE (1), 4/A (1), 424B4 (1), 8-A12B (1), 8-K/A (1), ARS (1), CERTNAS (1), D (1), DRS (1), DRS/A (1), S-1 (1), SC 13D (1), SC 14D9 (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 28, 2023
    Quarterly report (10-Q) Aug 14, 2023
    Proxy statement (DEF 14A) Apr 21, 2023
    Latest 8-K (8-K) Oct 11, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
    SEC EDGAROther events
  37. 37
    SEC EDGAROther events
  38. 38
    SEC EDGAROther events
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48